Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (269 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: treatedin subjectsweeksreceivingcurrently
  Phrases that lowered it: irritabilitymaleof agefemaleyears of
• Phase: 2 (raises risk) · Design
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: 17 (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Minimum age: 6 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders NCT01064973 · started 2010 · scored riskier than 65% of active trials terminated
• Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders NCT01288716 · started 2011 · scored riskier than 40% of active trials completed
• Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders NCT01706523 · started 2011 · scored riskier than 66% of active trials terminated
• Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome NCT00788073 · started 2008 · scored riskier than 21% of active trials completed
• Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148 NCT04258839 · started 2020 · scored riskier than 22% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.